Gemma Biotherapeutics, co-founded in 2024 by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director’s Professor in Penn Medicine, secured $34 million in seed funding to support clinical trials through a partnership with Brazil’s Ministry of Health. Read more here.